Date of filling in this questionnaire or last update: 12/01/2022
1. IDENTIFICATION & BASIC DESCRIPTION
Cohort name
  NINFEA
Country
 

  • Italy

Please provide any other information on the cohort location/s if needed
  Being a web-based cohort, participants can come from any country, even though most are Italian.
Name
  Lorenzo Richiardi
Institution
  Università degli Studi di Torino - Dipartimento Scienze Mediche
Email
  lorenzo.richiardi@unito.it
Phone
  +39 011 6334673
Name
  Milena Maule
Institution
  Università degli Studi di Torino - Dipartimento Scienze Mediche
Email
  milena.maule@unito.it
Phone
  +39 011 6334628
Website
 

  • https://www.progettoninfea.it/

Name of committee
  Comitato Etico Interaziendale AOU Città della Salute e della Scienza di Torino - AO Ordine Mauriziano - ASL Città di Torino
Or provide website
 

  • https://www.progettoninfea.it/

Contact Principal Investigator (name)
  Lorenzo Richiardi
Participation in pooled analyses
 

  • The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).

Main aim of cohort, please briefly describe the main objectives of the cohort
  NINFEA aims to investigate environmental and genetic risk factors for maternal complications during pregnancy, for intrauterine growth restriction/problematic fetal development, etiology of congenital anomalies, exposures and individual and genetic factors that increase the risk of occurrence of certain diseases / conditions during childhood and adolescence.
Study design (please select as many as appropriate)
 

  • Prospective cohort

Source population (please select as many as appropriate)
 

  • Mother-child cohort

Inclusion criteria
  The cohort includes babies born to pregnant women who have enough knowledge of the Italian language and the use of the internet to complete online questionnaires
Enrollment
  Completed
Age range at entry (main cohort)
 

Minimum Maximum Mean
33.3

Women at enrollment
  7500
2. OUTCOME FOLLOW-UP
Type of data for outcome follow-up (please select as many as appropriate)
 

  • Active (contact with participants)

Active (contact with participants) (specify)
 

  • Active follow-up is managed centrally by contacting women via e-mail, telephone or post and inviting them to fill in the online questionnaires.

First follow-up period (provide year)
  2005
Last follow-up period (provide year)
  2020
Number of follow-ups after baseline (provide number)
  6
Participation at last follow-up (if known)
  69
Comments
  The reported participation rate is referred to 10 years follow-up. All NINFEA follow-ups are ongoing.
3. OCCUPATIONAL EXPOSURES
Source of exposure data collected (please select as many as appropriate)
 

  • Questionnaire, Personal (Self-reporting or interview)

Occupational history/time frame
  Current, at enrollment
Occupational coding performed
  Yes
Occupation (specify coding system used)
 

  • ISCO-88

Methods for exposure assessment (please select as many as appropriate)
 

  • Self-report

4. OUTCOMES EVALUATED
Baseline - type of outcome data collected (select more than one if applicable)
 

  • Questionnaire, individual (self-recording or interview)

Follow-up - type of outcome data collected (select more than one if applicable)
 

  • Questionnaire, individual (self-recording or interview)

Outcome type (please select as many as appropriate)
 

  • Morbidity

Diagnostic groups based on ICD10
 

  • B Viral infections, type of microorganisms*
  • B99 Other and unspecified infectious diseases, type of microorganisms*
  • D Diseases of blood and blood-forming organs excl. leukemia
  • E Endocrinological disease
  • E Malnutrition and obesity
  • E Metabolism disease
  • F Mental disorders
  • G Disease in the nervous system
  • J Respiratory disease
  • K Diseases of oesophagus, stomach, duodenum and appendix
  • K Hernia, colon and intestine disease
  • K Diseases of peritoneum, liver
  • L Skin, nail and hair disorders
  • M Arthritis, arthrosis, systemic connective disorders, spine disorders
  • N Kidney, renal pelvis disease
  • N Male and female related disorders
  • O+P Pregnancy and labour
  • Q After birth – child disorders

B Viral infections, type of microorganisms
 

  • Cytomegalovirus
  • Hepatitis (A,B,C,E)
  • Human herpes virus
  • Human papilloma virus
  • Influenza virus
  • Rubella virus
  • Varicella zoster virus

B99 Other and unspecified infectious diseases, type of microorganisms
 

  • Chlamydia
  • Other infections, please state

B99 Other and unspecified infectious diseases, type of microorganisms | Other (specify)
  Toxoplasmosis
D Diseases of blood and blood-forming organs excl. leukemia
 

  • Anaemia, unspecified

E Endocrinological disease
 

  • Thyroidea
  • Diabetes mellitus

E Malnutrition and obesity
 

  • Vitamin deficiency, unspecified

E Metabolism disease
 

  • Hypercholesterolemia

F Mental disorders
 

  • Depression
  • Eating disorders
  • Other mental disorder, not otherwise specified

G Disease in the nervous system
 

  • Multiple sclerosis
  • Epilepsy
  • Migraine
  • Sleep disorders

J Respiratory disease
 

  • Influenza
  • Acute bronchitis
  • Vasomotor and allergic rhinitis
  • Asthma

K Diseases of oesophagus, stomach, duodenum and appendix
 

  • Gastric ulcer
  • Duodenal ulcer

K Hernia, colon and intestine disease
 

  • Crohn's disease
  • Ulcerative colitis

K Diseases of peritoneum, liver
 

  • Other, please state

K Diseases of peritoneum, liver | Other (specify)
  Viral hepatitis
L Skin, nail and hair disorders
 

  • Atopic dermatitis

M Arthritis, arthrosis, systemic connective disorders, spine disorders
 

  • Rheumatoid arthritis

N Kidney, renal pelvis disease
 

  • Urolithiasis
  • Other, please state

N Kidney, renal pelvis disease | Other (specify)
  Recurrent urinary infections
N Male and female related disorders
 

  • Inflammation of vagina and vulva
  • Endometriosis
  • Other disorders of female genital and reproductive organs
  • Abnormal menstrual cycle
  • Female infertility
  • In vitro fertilisation
  • Spontaneous abortion
  • Molar pregnancy
  • Other, please state

N Male and female related disorders | Other (specify)
  vaginal candidiasis, cervical dysplasia, uterine myomas and fibroids, ovarian cysts
O+P Pregnancy and labour
 

  • Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium
  • Eclampsia in pregnancy, labour or puerperium
  • Excessive vomiting in pregnancy
  • Infections of genito-urinary tract in pregnancy
  • Diabetes mellitus in pregnancy
  • Other specified pregnancy-related conditions
  • Complications of labour and delivery
  • Preterm delivery
  • Extremely low birth weight
  • Other low birth weight
  • Exceptionally large baby
  • Foetal death of unspecified cause

Q After birth – child disorders
 

  • Congenital malformations of the nervous system incl. the brain
  • Congenital malformations of the circulatory system
  • Congenital malformations of the respiratory system
  • Cleft lip and cleft palate
  • Congenital malformations of digestive system
  • Congenital malformations of genital organs
  • Congenital malformations of the urinary system
  • Congenital malformations and deformations of the musculoskeletal system
  • Down's syndrome
  • Turner's syndrome
  • Klinefelter's syndrome

Other health related outcomes
 

  • Lifestyle change
  • Sleep
  • Work participation

5. BIOLOGICAL SAMPLES & ANALYSIS
Biological samples collected
 

  • Other

Specify: Other
  saliva
Biological processing
 

  • DNA

6. Other Information
 

  • Alcohol
  • Anthropometry
  • Demographics
  • Diet
  • Education
  • Environmental, air pollution
  • Environmental other (specify)
  • Medical history
  • Physical exercise
  • Residential history
  • Socioeconomic status
  • Smoking
  • Other (specify)

Specify: Environmental other
  Urban environment, green spaces, light, traffic, temperature, humidity, rural areas
Specify: Other
  Chemical substances
Please describe plans that are funded or most likely to be funded
  The 16-year follow-up will start during 2021 and will include a questionnaire focused on adolescent health and lifestyle (completed by adolescents) and a questionnaire completed by mothers which will assess both child and maternal health, as well as the household characteristics and living environment.
Project LifeCycle - European CHILD cohort network with harmonized data on most of the exposures/lifestyle factors/reproductive outcomes and child health.
ATHLETE - We will investigate how the exposome at different ages during early life is shaped by SEP, geographical deprivation and urbanization.